retatrutide nonalcoholic fatty liver disease nash trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic disease: a randomized phase 2a Fatty Liver Disease Clinical Trials

While bloating (often described as abdominal distension in clinical terms) is reported by patients, it is generally less commonly reported than nausea or diarrhoea

compounding pharmacies when commercially available (FDA-approved) treatments are not suitable for an individual patient

Retatrutide and exercise are both critical in transforming body composition by reducing fat mass and preserving or increasing muscle

- May lead to weight loss as a secondary benefit

Look at the alternative: the PlexusDx Weight Management Protocols provide month-to-month tirzepatide in injection and oral formats, or take the Precision Peptide Genetic Test to read your metabolic pathway first